LY4086940
/ Eli Lilly
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
August 20, 2026
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
(clinicaltrials.gov)
- P1 | N=219 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed
Trial completion • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus
June 17, 2026
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
(clinicaltrials.gov)
- P1 | N=216 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting
Enrollment closed • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus
April 18, 2026
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
(clinicaltrials.gov)
- P1 | N=216 | Recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Apr 2026 ➔ Jul 2026 | Trial primary completion date: Apr 2026 ➔ Jul 2026
Trial completion date • Trial primary completion date • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus
May 30, 2025
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
(clinicaltrials.gov)
- P1 | N=165 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting
Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus
1 to 4
Of
4
Go to page
1